Arthur Klausner

Bio

A seasoned life sciences venture capitalist, Mr.Klausner has a total of 18 years of experience at Domain Associates (1990-2004) and Pappas Ventures (2005-2009). During that time, he has been involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. Mr. Klausner has been a board member at Santarus (IPO in 2004, Nasdaq: SNTS), X-Ceptor (acquired by Exelixis in 2004), Orexigen (IPO in 2007, Nasdaq: OREX), Altea Therapeutics, CeNeRx BioPharma, Gentis, and Syndax Pharmaceuticals, and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005), Cerexa (acquired by Forest Laboratories in 2007), and Optherion; and currently serves on the Board of Directors of Neurotez (a privately held biotherapeutics company focused on Alzheimer’s disease). Mr. Klausner is on the Advisory Boards of Edge Therapeutics and Northeast Securities, and is also an advisor to Advanced Molecular Design. Mr. Klausner began his venture capital career after earning an M.B.A. at the Stanford University Graduate School of Business. While attending business school, he completed summer internships emphasizing corporate planning and market research functions at ImClone Systems and Neurogen, two start‑up biopharmaceutical companies that subsequently went public. Previously, he had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. Mr. Klausner has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a range of pharmaceutical and biotechnology companies. His undergraduate degree in Biology is from Princeton University. Mr. Klausner is also a biotechnology, specialty pharmaceutical and medical device advisor to the FCG Life Sciences Practice, and a member of the firm’s Transaction Selection Committee.